Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 5;9(11):e0004196.
doi: 10.1371/journal.pntd.0004196. eCollection 2015 Nov.

Multiple Origins of Mutations in the mdr1 Gene--A Putative Marker of Chloroquine Resistance in P. vivax

Affiliations

Multiple Origins of Mutations in the mdr1 Gene--A Putative Marker of Chloroquine Resistance in P. vivax

Mette L Schousboe et al. PLoS Negl Trop Dis. .

Abstract

Background: Chloroquine combined with primaquine has been the recommended antimalarial treatment of Plasmodium vivax malaria infections for six decades but the efficacy of this treatment regimen is threatened by chloroquine resistance (CQR). Single nucleotide polymorphisms (SNPs) in the multidrug resistance gene, Pvmdr1 are putative determinants of CQR but the extent of their emergence at population level remains to be explored.

Objective: In this study we describe the prevalence of SNPs in the Pvmdr1 among samples collected in seven P. vivax endemic countries and we looked for molecular evidence of drug selection by characterising polymorphism at microsatellite (MS) loci flanking the Pvmdr1 gene.

Methods: We examined the prevalence of SNPs in the Pvmdr1 gene among 267 samples collected from Pakistan, Afghanistan, Sri Lanka, Nepal, Sudan, São Tomé and Ecuador. We measured and diversity in four microsatellite (MS) markers flanking the Pvmdr1 gene to look evidence of selection on mutant alleles.

Results: SNP polymorphism in the Pvmdr1 gene was largely confined to codons T958M, Y976F and F1076L. Only 2.4% of samples were wildtype at all three codons (TYF, n = 5), 13.3% (n = 28) of the samples were single mutant MYF, 63.0% of samples (n = 133) were double mutant MYL, and 21.3% (n = 45) were triple mutant MFL. Clear geographic differences in the prevalence of these Pvmdr mutation combinations were observed. Significant linkage disequilibrium (LD) between Pvmdr1 and MS alleles was found in populations sampled in Ecuador, Nepal and Sri Lanka, while significant LD between Pvmdr1 and the combined 4 MS locus haplotype was only seen in Ecuador and Sri Lanka. When combining the 5 loci, high level diversity, measured as expected heterozygosity (He), was seen in the complete sample set (He = 0.99), while He estimates for individual loci ranged from 0.00-0.93. Although Pvmdr1 haplotypes were not consistently associated with specific flanking MS alleles, there was significant differentiation between geographic sites which could indicate directional selection through local drug pressure.

Conclusions: Our observations suggest that Pvmdr1 mutations emerged independently on multiple occasions even within the same population. In Sri Lanka population analysis at multiple sites showed evidence of local selection and geographical dispersal of Pvmdr1 mutations between sites.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. The Pvmdr1 gene and the relative position of the chosen MS.
The identified SNPs within Pvmdr1 and the two chosen MS downstream of the Pvmdr1 gene; m9.5 (9,489 bp downstream of Pvmdr1), m10.1 (10,120 bp downstream) and the two upstream MS: m10.4 (10,420 upstream) and m43.1 (43,168 bp upstream) are shown.
Fig 2
Fig 2. Pvmdr1 polymorphism in Plasmodium vivax samples collected at 8 geographical sites.
Four Pvmdr1 alleles were detected in the study abbreviated as TYF, MYF, MYL and MFL. The TYF wild-type is shown in blue, MYF (single mutant, T958M) in yellow, MYL (double mutant, T958M+F1076L) in green, and MFL (triple mutant T958M+Y976F+F1076L) in red. The number of positive samples from each site is shown on the map in brackets, and the number of alleles and percentage frequency overall are shown in the legend.
Fig 3
Fig 3. Genetic diversity of the Plasmodium vivax mdr1 gene in P. vivax samples collected at 9 malaria endemic districts of Sri Lanka.
Three different genotypes were detected in the samples from Sri Lanka named MYF(yellow), MYL(green) and MFL(red). MYF (single mutant, T958M), MYL (double mutant, T958M and F1076L) and MFL (triple mutant). The number of positive samples from each district is mentioned in brackets.
Fig 4
Fig 4. Plasmodium vivax mdr1 combined with flanking microsatellite variation in P. vivax samples collected at 9 malaria endemic districts of Sri Lanka.
The size of the pie charts reflects the sample size, while the segments illustrate the frequency of combined Pvmdr SNP+ microsatellite haplotypes. Grey color segment indicates the proportion of the sample which consisted of unique 'singleton' haplotypes while the other colors indicate the proportion of each repeated haplotype. The black lines indicate sharing of a specific haplotype between two sites and multiple lines indicate the number of haplotypes shared between given sites.

References

    1. ALVING AS, HANKEY DD, COATNEY GR, JONES R Jr., COKER WG, GARRISON PL, et al. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg 1953. November;2(6):970–6. - PubMed
    1. ALVING AS, JOHNSON CF, TARLOV AR, BREWER GJ, KELLERMEYER RW, CARSON PE. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ 1960;22:621–31. - PMC - PubMed
    1. Lopez-Antunano FJ. Is primaquine useful and safe as true exo-erythrocytic merontocidal, hypnozoitocidal and gametocidal antimalarial drug? Salud Publica Mex 1999. September;41(5):410–9. - PubMed
    1. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989. November 18;2(8673):1183–4. - PubMed
    1. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009. July;22(3):508–34. 10.1128/CMR.00008-09 - DOI - PMC - PubMed

Publication types